Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Active Ankylosing Spondylitis
NCT04507659Phase 2Completed
- Sponsor
- Zelgen
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in ankylosing spondylitis (AS), sponsored by Zelgen. Started Dec 2020; status: completed.
02
Drugs
jaktinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04507659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507659.